Nanommune, Velox to offer microarray testing, consulting for COVID-19

LabPulse.com staff writers
Jul 2, 2020
2020 07 02 23 31 0378 Handshake Meeting 400

Medical biotechnology company Nanommune and clinical diagnostics company Velox Biosystems have partnered to offer rapid laboratory testing and consulting services.

The partnership aims to increase the adoption of high-plex microarray platforms among clinicians, laboratories, and researchers who want to use microarray technology for COVID-19 diagnostics but lack the experience and capabilities to perform high-throughput testing.

Nanommune and Velox will leverage their diagnostic testing experience to provide end-to-end testing and consulting services for microarray antibody and antigen assays. The companies are also working closely together to launch a COVID-19 immune profiling service and other products based on the microarray technology, according to Velox Chief Executive Officer Byron Shen.

Latest in Gene silencing and gene editing
Crispr Cas9 Gene Editing Social
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
March 15, 2023
Ms Crisp Rimage Social
Sherlock Biosciences nabs additional patent rights to Cas12 enzyme for CRISPR diagnostics
February 21, 2023
Crispr Cas9 Gene Editing Social
Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption
February 1, 2023
Crispr Cas9 Gene Editing Social
AI tool makes speedy gene-editing possible, offers alternative to CRISPR
January 26, 2023
Related Stories
2020 06 24 16 50 8425 Pathogen Dx 400
Gene silencing and gene editing
PathogenDx partners with Bertin Instruments on airborne COVID-19 test
2019 05 15 19 42 9457 Gavel3 400
Lawsuit
Feds arrest president of blood testing firm on fraud charges
2020 06 04 21 46 9284 2020 06 04 H Vivo 400
Gene silencing and gene editing
Firm offers COVID-19 full sample antibody testing for U.K. employers
2020 05 12 22 10 0813 Child Speech Therapy 400
Research Consortium
Real-world study: Genetic testing appears underused in autism
More in Gene silencing and gene editing
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Glow-in-the-dark proteins, developed from the luciferase found in bioluminescent creatures, may make viral disease diagnosis quicker and easier, according to the researchers.
March 15, 2023
Crispr Cas9 Gene Editing Social
Sherlock Biosciences nabs additional patent rights to Cas12 enzyme for CRISPR diagnostics
Sherlock Biosciences has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, as well as to additional intellectual property for Cas12 and Cas13 obtained from the Broad Institute.
February 21, 2023
Ms Crisp Rimage Social
Sherlock Biosciences acquires Sense Biodetection to drive CRISPR-based test adoption
The acquisition enables Sherlock to combine its CRISPR, synthetic biology, and artificial intelligence technologies with Sense's instrument-free diagnostic hardware and rapid molecular amplification chemistries.
February 1, 2023
Crispr Cas9 Gene Editing Social
AI tool makes speedy gene-editing possible, offers alternative to CRISPR
An artificial intelligence program may enable the first simple production of customizable proteins called zinc fingers to treat diseases by turning genes on and off.
January 26, 2023
Crispr Cas9 Gene Editing Social
Discovery of destructive CRISPR enzyme opens up diagnostic, therapeutic applications for molecular scissors
In a pair of Nature papers, researchers describe the structure and function of Cas12a2, which binds and cuts target DNA to shut off a specific gene so that the enzymes can be used as molecular scissors.
January 4, 2023
Crispr Cas9 Gene Editing Social
Sherlock Biosciences licenses Wyss Institute nucleic acid amplification technology
Sherlock Biosciences will integrate the method with its CRISPR-based Sherlock platform. The aim is to develop diagnostic assays that can detect pathogen- or disease-related nucleic acids at the point-of-need without instruments.
October 17, 2022
Ms Crisp Rimage
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Quest launches long-COVID testing panels for consumers
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
More in Gene silencing and gene editing
Allelica launches polygenic risk score analysis as LDT
The firm said its tests are made possible through a partnership with Clinical Enterprise, a CLIA-certified, CAP-accredited laboratory located in Framingham, MA.
September 20, 2022
2022 08 23 15 47 2774 Dna Sequencing Data Analysis 400
Nucleai, Propath partner on immuno-oncology panel
Propath will develop a novel protocol using the Lunaphore Comet platform for analysis of 30 high-value protein targets from a single tissue section. The platform enables rapid development of highly multiplexed panels, with robust and reproducible staining, Nucleai said.
September 20, 2022
2020 03 25 23 27 0591 Hands Shaking Deal 400
‘Father of microarray technology’ convicted in $77M fraud scheme
Mark Schena participated in a scheme to mislead investors, commit healthcare fraud, and pay illegal kickbacks in connection with the submission of more than $77 million in false and fraudulent claims for such testing, the U.S. Department of Veterans Affairs (VA), Office of Inspector General (OIG), announced Thursday.
September 8, 2022
2022 09 09 15 50 1647 Prison Jail Money 400
Thermo Fisher promotes new mass spectrometry instrument
The instrument is called Orbitrap Ascend Tribrid, and it offers capability for multiplexed proteomics and native protein characterization, according to Thermo Fisher. It can analyze more samples at lower concentrations, and features an ion source for calibration the company calls Auto-Ready.
August 28, 2022
2022 08 29 21 41 5127 Liquid Chromatography Hplc Mass Spectrometry 400
Quotient Q1 2023 revenues drop on customer order change
For the quarter ended June 30, the Eysins, Switzerland-based firm posted a net loss of $38.9 million, or $.37 per share, compared to $27.3 million, or $.27 per share, in fiscal Q1 2022.
August 8, 2022
2020 06 18 17 24 6922 Immunoassay Analysis 400
Qiagen expands PCR portfolio, launches custom assay service
New solutions are available with 10 new QIAcuity Cell and Gene Therapy dPCR Assays for use in adeno-associated virus (AAV) titer quantifications. Custom assay design provides users with access to multiplex assays for use beyond biopharma purposes.
July 26, 2022
2020 04 28 19 25 1337 Sequencing Dna Rna Pcr 400
Page 1 of 5
Next Page